nucleotides. Since cyclic GMP is consistently found within the granular cytoplasmic region of the cell, it is likely, as others have suggested (8, 13, 21) The first issue relates to criteria for diagnosing hyperactivity. Although there is continuing debate regarding the propriety or utility of using the diagnostic label "hyperactivity" (hyperkinetic syndrome, minimal brain dysfunction), the -label remains widely applied. The descriptors of and criteria for the syndrome are undergoing change (2), but as far as we are aware, Swanson and Kinsbourne (3) are the only advocates of using drug response as a confirmatory criterion for a diagnosis of hyperactivity. Thus, it is possible that many of their so-called "nonhyperactives" would indeed be considered hyperactive by most researchers in this area. The general position of professionals is perhaps most clearly represented by the continuing efforts to predict which hyperactive children will respond favorably to stimulant medication (4). Moreover, recent data indicating that the cognitive and behavioral responses of hyperactive and normal children are qualitatively similar (5) appear to invalidate unequivocally any further use of drug response as a diagnostic criterion in hyperactivity. The second point concerns the between-group focus taken by Swanson and Kinsbourne (1) which overlooks an important aspect of the data. Interpreting the three-way interaction by analyzing the simple interaction effects of challenge and test time, they concluded that the dye challenge affects performance of hyperactives but not of "nonhyperactives." However, even a cursory examination of their figure 1 (1 Comparison of group means derived from their figure 1 suggests significant and similar deteriorations in performance over time in all conditions except the hyperactives after placebo challenge. Thus the data do not permit the conclusion that "the performance of the nonhyperactive group was not affected by the challenge with the food dye blend." Under placebo conditions baseline data reflected the expected superiority of the "nonhyperactive" group, but by the final test session their performance had fallen to a level similar to the hyperactive group which showed no change. Why did the "nonhyperactives" manifest the observed deterioration in performance under the placebo condition? This question must be answered before the findings of the challenge study can be interpreted unambiguously.
Comparison of group means derived from their figure 1 suggests significant and similar deteriorations in performance over time in all conditions except the hyperactives after placebo challenge. Thus the data do not permit the conclusion that "the performance of the nonhyperactive group was not affected by the challenge with the food dye blend." Under placebo conditions baseline data reflected the expected superiority of the "nonhyperactive" group, but by the final test session their performance had fallen to a level similar to the hyperactive group which showed no change. Why did the "nonhyperactives" manifest the observed deterioration in performance under the placebo condition? This question must be answered before the findings of the challenge study can be interpreted unambiguously.
Finally, the children in the study (1) were involved in a "controlled implementation of the Feingold diet" although no assessment of the diet treatment itself is presented. It should be emphasized that the clinical signifcance of any "challenge effect" will not be established until it is demonstrated that the same children (or some subset) giving a challenge response aiso show a good diet response in controlled study. Only then could we attribute the day-to-day behav-SCIENCE, VOL. 211, 23 JANUARY 1981 ior and learning problems of specific hyperactive children to the same pharmacological or toxic mechanism demonstrated in the challenge situation. (6) (7) (8) showing a similarity of response to stimulant drugs by 15 hyperactive and 14 normal children should "invalidate unequivocally any further use of drug response as a diagnostic criterion in hyperactivity." The results of the NIMH study (6) (7) (8) should be qualified by the principle of task specificity of response to stimulant drugs (9): stimulant drugs may improve performance of normal adults only on low-level intellectual tasks but not on high-level tasks, except when abnormal conditions exist (for example, sleep deprivation or extreme boredom).
Weingartner et al. (7, p. 34 ) and Rapoport et al. (8, p. 941 ) have challenged the usual interpretation of task specificity of response to stimulants on the basis of free and cued recall data from a memory task in which subjects were presented with material once for a few seconds and were then distracted by another task to prevent rehearsal. We (10), too, have used this type of test. We agree that "performance of normal men and hyperactive and normal boys improved on this task" (8, p. 941) and that drug response on this test does not have diagnostic significance. But the results from other tests may be different. On a pairedassociate or serial learning test requiring rehearsal and repetition of the same material for 20 to 30 minutes, the performance of normal adults is not enhanced and may even be significantly impaired by stimulants (11, 12) . Furthermore, on a memory scanning task requiring rehearsal, doses of methylphenidate equivalent to or lower than 0.5 mg of d-amphetamine per kilogram of body weight produce "'behavior toxicity" in hyperactive children (13, 14) and may even reduce performance below the level on placebo in other clinical groups of children (15) .
We recognize the importance of the NIMH study (6) (7) (8) 
